Spaulding to present performance metrics at the American Society for Clinical Pharmacology and Therapeutics
Online PR News – 08-March-2016 – West Bend – Spaulding Clinical Research, LLC, a full-service CRO announced today that they will be in attendance at the American Society for Clinical Pharmacology and Therapeutics’ (ASCPT) 2016 Annual Meeting. The event is scheduled to take place at the Hilton Bayfront in San Diego, California a from March 8th through the 12th. Spaulding Clinical Research will be exhibiting at Booth #54 and will be showcasing their industry leading Clinical Pharmacology and ECG Core Laboratory Services.
Company associates will be available to discuss how Spaulding Clinical’s metrics could help a Sponsor achieve their study goals. “It’s been five years since we began publically reporting our study metrics that substantiate claims of high-quality study execution. Not only did we make our metrics available to Sponsors, but as a reminder we also placed them on the back of every Spaulding associate business card,” stated Daniel Selness, Chief Strategy Officer at Spaulding Clinical Research. Mr. Selness continued, “To our knowledge, none of our competitors have followed the Spaulding lead in making this information generally available to potential customers.”
The American Society for Clinical Pharmacology and Therapeutics (ASCPT) is the leading forum for the exchange, development and integration of translational science into the drug development continuum from discovery to safe and effective medication use. The Society is the largest scientific and professional organization serving the Discipline of Clinical Pharmacology. Headquartered in Alexandria, VA, ASCPT was founded in 1900 and has over 2,200 members worldwide.
About Spaulding Clinical Research, LLC
Spaulding Clinical Research, LLC (SCR) is a full-service CRO providing Phase I drug development and Phase I-IV Core ECG Laboratory services. SCR operates a 200 bed, fully paperless, Clinical Pharmacology Unit featuring 96, full 12-lead telemetry beds and a 12-bed unit for First-In-Human /SAD/MAD trials.